v3.26.1
Stock-Based Compensation (Tables)
 6 Months Ended
Jun. 30, 2026
Share-Based Payment Arrangement [Abstract]  
Schedule of Stock-Based Compensation Expense and Related Income Tax Benefit Stock-based compensation expense by statement of operations caption and the related income tax benefit were as follows:
Three Months Ended June 30,Six Months Ended June 30,
(In thousands)2026202520262025
Cost of sales$12 $12 $25 $28 
Research and development expenses97 124 236 282 
Selling, general and administrative expenses:
Employees
145 1,217 542 2,493 
Outside directors
267 296 486 630 
Total employee and director stock-based compensation expense$521 $1,649 $1,289 $3,433 
Income tax benefit$100 $185 $262 $432 
Schedule of Non-Vested Restricted Stock Award Activity
Non-vested restricted stock award activity was as follows:
Shares
(in thousands)		Weighted-Average Grant Date Fair Value
Non-vested at December 31, 2025
494 $8.25 
Granted160 4.03 
Vested(295)8.35 
Forfeited(77)6.39 
Non-vested at June 30, 2026
282 $6.33 
Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award
Non-vested performance stock award activity was as follows:
Shares
(in thousands)		Weighted-Average Grant Date Fair Value
Non-vested at December 31, 2025
744 $2.16 
Granted120 2.56 
Vested— — 
Forfeited(156)2.85 
Non-vested at June 30, 2026
708 $2.00 

The assumptions we utilized in the Monte Carlo simulation model and the resulting weighted average fair value of performance stock grants were the following:
Three Months Ended June 30,Six Months Ended June 30,
2026202520262025
Weighted average fair value of grants$2.56 $2.24 $2.56 $2.24 
Risk-free interest rate4.10 %3.84 %4.10 %3.84 %
Expected volatility54.00 %58.00 %54.00 %58.00 %
Expected life in years3.472.633.472.63
Schedule of Stock Option Activity
Stock option activity was as follows:    
Number of Options
(in thousands)		Weighted-Average Exercise PriceWeighted-Average Remaining Contractual Term
(in years)		Aggregate Intrinsic Value
(in thousands)
Outstanding at December 31, 2025
856 $24.29 
Granted10 4.02 
Exercised— — $— 
Forfeited/canceled/expired(122)$27.07 
Outstanding at June 30, 2026 (1)
744 $23.57 5.32$482 
Vested and expected to vest at June 30, 2026 (1)
744 $23.57 5.32$— 
Exercisable at June 30, 2026 (1)
446 $36.86 2.68$— 
(1)The aggregate intrinsic value represents the total pre-tax value (the difference between our closing stock price on the last trading day of the first quarter of 2026 and the exercise price, multiplied by the number of in-the-money options) that would have been received by the option holders had they all exercised their options on June 30, 2026. This amount will change based on the fair market value of our stock.
Schedule of Assumptions to Determine Weighted Average Fair Value of Stock Options
The assumptions we utilized in the Black-Scholes pricing model and the resulting weighted average fair value of stock option grants were the following:
Three Months Ended June 30,Six Months Ended June 30,
2026202520262025
Weighted average fair value of grants$2.21 $— $2.21 $— 
Risk-free interest rate4.24 %— %4.24 %— %
Expected volatility54.21 %— %54.21 %— %
Expected life in years5.750.005.750.00